Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Ticker
$IVA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
116
ISIN
US46124U1079
Website
Inventiva Metrics
BasicAdvanced
$431M
-
-$3.61
0.97
-
Price and volume
Market cap
$431M
Beta
0.97
52-week high
$4.05
52-week low
$2.67
Average daily volume
24K
Financial strength
Current ratio
0.924
Quick ratio
0.903
Long term debt to equity
-95.626
Total debt to equity
-169.953
Interest coverage (TTM)
-1.13%
Profitability
EBITDA (TTM)
-113.341
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,251.10%
Operating margin (TTM)
-662.57%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$152,370
Management effectiveness
Return on assets (TTM)
-63.60%
Return on equity (TTM)
265.67%
Valuation
Price to revenue (TTM)
11.036
Price to book
-2.37
Price to tangible book (TTM)
-2.37
Price to free cash flow (TTM)
-1.803
Free cash flow yield (TTM)
-55.46%
Free cash flow per share (TTM)
-169.14%
Growth
Revenue change (TTM)
-36.43%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
18.36%
10-year revenue growth (CAGR)
9.11%
3-year earnings per share growth (CAGR)
34.47%
10-year earnings per share growth (CAGR)
15.22%
Bulls say / Bears say
Positive Phase II clinical trial results for lanifibranor in treating NAFLD and Type 2 diabetes, meeting primary and secondary endpoints, suggest strong efficacy and safety profiles. (investorplace.com)
Initiation of coverage by UBS Group with a 'neutral' rating and a $3.00 price target indicates growing analyst interest and potential for future positive revisions. (marketbeat.com)
Stifel Nicolaus maintains a 'buy' rating with a $17.00 price target, reflecting confidence in the company's prospects despite financial challenges. (defenseworld.net)
Stifel Nicolaus reduced Inventiva's price target from $20.00 to $17.00, citing financial stability concerns and limited financing options. (investing.com)
As of June 30, 2024, Inventiva reported cash and cash equivalents of €10.1 million, indicating a limited cash runway and potential need for additional financing. (markets.businessinsider.com)
The NATiV3 Phase III trial experienced delays, with enrollment completion now projected for the first half of 2025, potentially impacting timelines for product approval and commercialization. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Inventiva News
AllArticlesVideos
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
GlobeNewsWire·1 month ago
Inventiva reports 2025 First Quarter Financial Information¹
GlobeNewsWire·1 month ago
Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva stock?
Inventiva (IVA) has a market cap of $431M as of June 30, 2025.
What is the P/E ratio for Inventiva stock?
The price to earnings (P/E) ratio for Inventiva (IVA) stock is 0 as of June 30, 2025.
Does Inventiva stock pay dividends?
No, Inventiva (IVA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Inventiva dividend payment date?
Inventiva (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva?
Inventiva (IVA) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.